How to buy Alx Oncology Holdings  stock (ALXO)

Alx Oncology Holdings  is a biotechnology business based in the US. Alx Oncology Holdings  shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.62 – the same closing value as a week prior. Alx Oncology Holdings  employs 89 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Alx Oncology Holdings  stock

Buy Alx Oncology Holdings  stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Alx Oncology Holdings  stock price (NASDAQ: ALXO)

Use our graph to track the performance of ALXO stocks over time.

Alx Oncology Holdings  shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.62
52-week range	$1.19 - $17.83
50-day moving average more info button	$1.51
200-day moving average more info button	$6.27
Wall St. target price	$7.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.97

Is it a good time to buy Alx Oncology Holdings  stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alx Oncology Holdings  price performance over time

Historical closes compared with the close of $1.69 from 2024-12-26

1 week (2024-12-20)	4.32%
1 month (2024-11-29)	14.19%
3 months (2024-09-27)	-14.21%
6 months (2024-06-28)	-71.97%

1 year (2023-12-28)	-88.94%
2 years (2022-12-28)	-84.84%
3 years (2021-12-28)	22.26
5 years (2019-12-25)	N/A

Alx Oncology Holdings  financials

Gross profit TTM	$107,000
Return on assets TTM	-49.25%
Return on equity TTM	-98.94%
Profit margin	0%
Book value	$2.59
Market Capitalization more info button	$96.5 million

TTM: trailing 12 months

Alx Oncology Holdings  share dividends

We're not expecting Alx Oncology Holdings  to pay a dividend over the next 12 months.

Alx Oncology Holdings  share price volatility

Over the last 12 months, Alx Oncology Holdings 's shares have ranged in value from as little as $1.19 up to $17.825. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alx Oncology Holdings 's is 1.036. This would suggest that Alx Oncology Holdings 's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Alx Oncology Holdings  overview

ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc.

Frequently asked questions

null
What percentage of Alx Oncology Holdings  is owned by insiders or institutions?
Currently 1.969% of Alx Oncology Holdings  shares are held by insiders and 88.208% by institutions. How many people work for Alx Oncology Holdings ?
Latest data suggests 89 work at Alx Oncology Holdings . When does the fiscal year end for Alx Oncology Holdings ?
Alx Oncology Holdings 's fiscal year ends in December. Where is Alx Oncology Holdings  based?
Alx Oncology Holdings 's address is: 323 Allerton Avenue, South San Francisco, CA, United States, 94080 What is Alx Oncology Holdings 's ISIN number?
Alx Oncology Holdings 's international securities identification number is: US00166B1052